2020
Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlacebo
2018
Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects
Olten B, Bloch MH. Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2018, 84: 272-281. PMID: 29410000, DOI: 10.1016/j.pnpbp.2018.01.023.Peer-Reviewed Original ResearchConceptsRisk of sedationExtrapyramidal side effectsM4 receptorsReceptor binding profileWeight gainAntipsychotic medicationSide effectsGeneric inverse variance methodReceptor affinityAffinity of antipsychoticsIndividual antipsychotic medicationsInverse variance methodTreatment of schizophreniaExtrapyramidal symptomsQTc prolongationM1 receptorsProlactin increaseQT prolongationAntipsychotic agentsH1 receptorsHigh riskMedicationsSedationBinding profileReceptors
2017
Antipsychotics for aggression in adults: A meta-analysis
van Schalkwyk GI, Beyer C, Johnson J, Deal M, Bloch MH. Antipsychotics for aggression in adults: A meta-analysis. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 81: 452-458. PMID: 28754408, DOI: 10.1016/j.pnpbp.2017.07.019.Peer-Reviewed Original ResearchConceptsTreatment of aggressionAntipsychotic medicationNon-pharmacologic interventionsEffect sizeChoice of agentSignificant dose effectSignificant morbidityCochrane LibraryAntipsychotic agentsDopamine antagonistsPsychiatric illnessIrritable moodMultiple diagnosesClinical decisionAntipsychoticsSpecific agentsSearch termsSmall effect sizesDiagnosisDose effectMedicationsSymptom dimensionsAggressive behaviorTreatmentAdults
2016
Commentary: Are alpha‐2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016)
Bloch MH. Commentary: Are alpha‐2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016). Journal Of Child Psychology And Psychiatry 2016, 57: 1005-1007. PMID: 27535650, DOI: 10.1111/jcpp.12592.Peer-Reviewed Original ResearchConceptsAlpha-2 agonistsComorbid ADHDComprehensive Behavioral InterventionAdrenergic receptor agonistAgonist medicationsAntipsychotic medicationReceptor agonistPrimary treatmentTic disordersSystematic reviewMedicationsBehavioral interventionsAgonistsEffects of ADHDEfficacyTreatmentADHDChildrenPossible explanationPatients
2015
Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy. Obstetrics And Gynecology 2015, 125: 1224-1235. PMID: 25932852, PMCID: PMC4418034, DOI: 10.1097/aog.0000000000000759.Peer-Reviewed Original ResearchConceptsAdverse birth outcomesGestational-age birthsAntipsychotic exposureNeonatal outcomesCohort studyBirth outcomesAntipsychotic medicationMajor malformationsBirth weightOdds ratioAntipsychotic medication exposureNeonatal birth weightPooled odds ratioPotential risk factorsUnexposed pregnanciesMedication exposurePreterm deliveryGestational ageAntipsychotic treatmentElective terminationPossible confoundersReproductive ageRisk factorsSpontaneous abortionSTUDY SELECTION